Home Injection & Infusion Support: The Operational Backbone of a Successful PSP in Egypt
Quick answer
For biologic and specialty therapies, the home visit is not a feature of the program — it is the program. A step-by-step look at how home injection and infusion support actually works in Egypt.
Home injection and infusion support appears as a single bullet point on almost every patient support program page in this market, including, until now, our own. That bullet point hides the part of the program that carries the most clinical risk, the most operational complexity, and the largest share of the cost.
For biologic and specialty therapies, the visit is not a feature of the program — it is the program. Everything else exists to make sure the right nurse reaches the right patient with the right therapy at the right time, and that what happened during that visit is documented and escalated correctly. The operational buyer on the pharma side, the person who actually has to sign off on whether a vendor can safely handle a biologic in a patient's home, needs more than a bullet point. This is that detail.
There is also a patient-facing stake worth naming up front. For a patient in a governorate two hours from the nearest infusion centre, home administration is the difference between a therapy that fits into their life and one that competes with it — and that is measurable in whether they are still on treatment six months later.
What a home injection or infusion visit actually involves
A properly run visit follows the same defined sequence every time, for every patient. The consistency is the point: it is what makes the visit auditable, trainable, and safe to scale across a nurse network.
- Pre-visit scheduling and confirmation: the visit is scheduled against the patient's dosing cycle, confirmed with the patient or caregiver ahead of time, and the nurse assignment is matched to the therapy's requirements and the patient's location.
- Therapy readiness and handling checks: the product is verified before administration — identity, dose, expiry, and storage condition, including cold-chain verification where the therapy requires it. A dose that fails these checks is not administered.
- Arrival, patient assessment, and safety checks: the nurse confirms patient identity, reviews how the patient has been since the last dose, checks for anything that would contraindicate administration today, and prepares a clean administration area.
- Administration: the injection or infusion is given according to the therapy's protocol, with technique reinforced and, where the patient is learning self-administration, demonstrated and observed.
- Post-administration monitoring window: the nurse remains with the patient for the observation period the therapy requires, watching for reaction and confirming the patient is stable before leaving.
- Documentation and handover: the visit is documented — dose given, patient status, anything observed — and any finding that needs clinical attention enters the escalation pathway the same day.
Nurse training and credentialing — what to ask a PSP partner
Every provider in this market will tell you their nurses are qualified. The useful question is narrower: qualified for what, verified by whom, and refreshed how often. These are the four areas worth interrogating in a vendor assessment.
| Area | What to ask for | Why it matters |
|---|---|---|
| Licensure and clinical background | Verified nursing registration and relevant clinical experience per nurse, not per company | The company's credentials are irrelevant if the nurse attending your patient does not hold them |
| Injection and infusion technique certification | Documented training on the administration route your therapy uses, with periodic reassessment | Technique errors in the home are invisible unless training is verified and refreshed |
| Cold-chain and product handling training | Training and documented procedure for temperature-sensitive therapies | A correctly given dose of an incorrectly stored product is still a failed dose |
| Adverse-event recognition and escalation | The specific protocol the nurse follows, and evidence they have been trained on it | The nurse is your program's only clinical observer in the room |
| Therapy-specific onboarding | Product-specific training before the first patient visit on a new program | Generic competence does not cover the specifics of a newly launched biologic |
Tell us where your enrolled or forecast patients are, and we will tell you plainly where we cover directly and how we handle everywhere else.
Check governorate coverageGeographic coverage — can this actually reach patients outside Cairo?
This is the question buyers ask most and get answered least honestly, so here is a straight answer about how coverage really works in Egypt.
Density is not uniform. Greater Cairo, Giza, and Alexandria support the deepest nurse networks, the shortest scheduling lead times, and the easiest coverage for last-minute changes. The Delta governorates and the major canal cities are reachable with planning. Upper Egypt and the more remote governorates are served, but with longer scheduling lead times and a network that is built patient by patient rather than assumed to be standing by.
- Ask for coverage to be described by governorate, not by phrases like "nationwide" — the word means very different things to different vendors in this market.
- Ask what the scheduling lead time is in the specific governorates where your patients actually are, not the national average.
- Ask how a new coverage area is opened: recruiting and credentialing a nurse in a governorate where a program has its first patient takes time, and you should know how much before you forecast enrollment there.
- Ask who covers a visit when the assigned nurse is unavailable — in thin-coverage areas this is where programs quietly fail.
An honest provider will describe their coverage as a map with different depths, because that is what it is. A provider who claims uniform nationwide capability for a specialty biologic has either not run one outside the major cities or is not being precise with you.
When something goes wrong — the escalation pathway
The value of a home program is not that nothing ever goes wrong. It is that when something does, there is a defined pathway rather than a judgement call made alone in a patient's living room.
- Capture at the point of observation: the attending nurse records what was observed during or after administration, using a defined format rather than free recollection later.
- Immediate clinical triage: anything requiring urgent attention follows the program's urgent pathway — stabilising the patient, contacting emergency services where indicated, and notifying the treating physician.
- Physician notification: the prescriber is informed of clinically relevant findings so that the treatment decision stays with the clinician who owns it.
- Safety reporting to the sponsor: adverse events are reported onward to the sponsoring pharma company through the reporting pathway agreed in the contract, within the timelines that pathway specifies.
- Program-level review: recurring findings are reviewed at the program level, because a pattern across several patients is information the sponsor's medical team needs and a single report does not convey.
How this connects back to adherence
Our guide on medication adherence argues that the practical barriers, not patient motivation, decide whether chronic therapy continues. Home administration removes the largest of those barriers outright: the recurring cost, travel, and time-off-work burden of reaching a clinic for every dose.
There is a second, less obvious effect. A patient who sees the same nurse every cycle has a clinical relationship with someone who will notice the side effect they were too embarrassed to mention on a phone call, and who can explain that it is expected. That combination — barrier removal plus continuity — is why the home visit is consistently the highest-impact component of a specialty PSP, and why it deserves more scrutiny in a vendor assessment than anything else on the module list.
Our patient support programs include home injection and infusion delivered by trained nurses, with documented visits and monthly reporting to the sponsor.
Explore patient support programsFrequently asked questions
Can the same nurse see a patient for every visit?
Continuity is the goal and, in areas with adequate network density, it is usually achievable — patients on long-term specialty therapy generally see a consistent nurse or a small named team. Full single-nurse continuity cannot be guaranteed everywhere, because leave, relocation, and staffing realities exist, and in thinner coverage areas a small rotating team is the honest answer. What should be guaranteed is that whoever attends has the same therapy-specific training and access to the same visit history, so the patient is not re-explaining their treatment each cycle.
What happens if a scheduled visit needs to be rescheduled at short notice?
Rescheduling is handled through the program coordinator rather than directly between patient and nurse, so the change is captured and the dosing schedule is protected. The practical constraint is geography: in Greater Cairo and Alexandria a same-week or often same-day alternative is realistic, while in thinner coverage governorates a short-notice change may shift the visit by a few days. Because dose timing matters clinically for many specialty therapies, any reschedule that risks falling outside the therapeutic window is flagged to the treating physician rather than absorbed silently.
Are home visits available on weekends?
Weekend and out-of-standard-hours visits are arranged where the therapy's dosing schedule requires it, and for programs where this is expected it should be written into the service scope rather than treated as an exception. It is worth raising during contracting: a program whose dosing cycle regularly lands on a Friday needs weekend capacity built into the staffing plan and the commercial model from the start, not negotiated visit by visit.
